Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present CSL Ltd. (OTC: CSLLY).

Full DD Report for CSLLY

You must become a subscriber to view this report.

Recent News from (OTC: CSLLY)

Hemophilia Association Of New Jersey Recognizes CSL CEO Paul Perreault As "Humanitarian Man Of The Year"
EAST BRUNSWICK, N.J. , May 14, 2018 /PRNewswire/ -- CEO and Managing Director of CSL Limited Paul Perreault has been named "Humanitarian Man of the Year" by the Hemophilia Association of New Jersey (HANJ). HANJ President David Lechner presented the award to Perreault at the ass...
Source: PR Newswire
Date: May, 14 2018 15:00
Patient Advocacy Groups Focus On Key Issues Affecting Patients
KING OF PRUSSIA, Pa. , April 26, 2018 /PRNewswire/ -- Patient advocacy groups in Michigan , Washington , Illinois , Missouri and South Carolina are preparing to meet the many challenges standing between patients with rare bleeding disorders and access to care. Their efforts ar...
Source: PR Newswire
Date: April, 26 2018 09:00
CSL Behring, Leader in Rare Diseases, Showcases Innovations in Neuromuscular Medicine (NMM) at the 2018 American Academy of Neurology Annual Meeting
KING OF PRUSSIA, Pa. , April 20, 2018 /PRNewswire/ -- Global biotherapeutics leader CSL Behring today announced that it will host an Industry Therapeutic Update at the 2018 annual meeting of the American Academy of Neurology ( AAN ) which will focus on neuromuscular medical rese...
Source: PR Newswire
Date: April, 20 2018 08:30
The Lancet publishes results demonstrating adjuvanted quadrivalent influenza vaccine provides significantly greater efficacy in children 6 through 23 months
CAMBRIDGE, Mass. , April 19, 2018 /PRNewswire/ -- Seqirus, a CSL company (ASX: CSL) and a leading innovator in influenza vaccines, today announced that The Lancet Respiratory Medicine published results from a Phase 3, randomized, head-to-head efficacy study that found an MF59®...
Source: PR Newswire
Date: April, 19 2018 14:02
Life-Saving Medicines Donated For Patients In The Developing World
MONTREAL and KING OF PRUSSIA, Pa. , April 12, 2018 /PRNewswire/ -- The World Federation of Hemophilia (WFH) and global biotherapeutics leader CSL Behring announced today that CSL Behring has shipped more than 10 million international units (IUs) of its medicines to treat hemophilia A ...
Source: PR Newswire
Date: April, 12 2018 10:15
Nasdaq Hosted 2nd Nasdaq International Designation Virtual Investor Conference
NEW YORK, April 03, 2018 (GLOBE NEWSWIRE) -- Nasdaq, Inc. (Nasdaq:NDAQ) announced the conclusion of its Nasdaq International Designation Virtual Investor Conference on March 21, 2018. In collaboration with BNY Mellon Depositary Receipts, Nasdaq welcomed select BNY Mellon Level I ADR Issuers...
Source: GlobeNewswire
Date: April, 03 2018 12:30
CSL Behring Announces First Patient Enrollment in Phase 3 Clinical Trial of CSL112 to Assess Reduction of Early Recurrent Cardiovascular Events in Heart Attack Survivors
KING OF PRUSSIA, Pa. , March 23, 2018 /PRNewswire/ -- CSL Behring, a global biotherapeutics leader, today announced the initiation of the AEGIS-II ( A poA-I E vent reducin G in I schemic S yndromes II) clinical trial and the first patient enrollment. The clinical trial will evalu...
Source: PR Newswire
Date: March, 23 2018 09:55
Forbes Magazine Names CSL Limited Among Top 50 Employers in the World
KING OF PRUSSIA, Pa. , March 20, 2018 /PRNewswire/ -- Forbes has named global biotechnology leader CSL Limited among the world's Top 50 employers, landing at no. 42 in the business media's annual Global 2000 survey. The Forbes list was compiled by Statista, which surveyed ...
Source: PR Newswire
Date: March, 20 2018 09:00
FDA Approves Hizentra® (Immune Globulin Subcutaneous [Human] 20% Liquid) for the Treatment of Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
KING OF PRUSSIA, Pa. , March 16, 2018 /PRNewswire/ -- Global biotherapeutics leader CSL Behring today announced that the U.S. Food and Drug Administration (FDA) approved Hizentra ®  (Immune Globulin Subcutaneous [Human] 20% Liquid) as the first and only subcutaneous immun...
Source: PR Newswire
Date: March, 16 2018 08:00
CSL Behring Receives Patient Impact Award For Subcutaneous Prophylactic Treatment To Prevent Hereditary Angioedema Attacks
KING OF PRUSSIA, Pa. , March 15, 2018 /PRNewswire/ -- Imagine not knowing when you might experience unpredictable, severe and painful swelling without warning in different parts of your body, including the abdomen, face and larynx. This is what it's like for patients with hereditary angio...
Source: PR Newswire
Date: March, 15 2018 09:00


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on CSLLY.

About CSL Ltd. (OTC: CSLLY)

Logo for CSL Ltd. (OTC: CSLLY)

CSL is a global specialty biopharmaceutical company that researches, develops, manufactures and markets biotherapies to treat and prevent serious and rare medical conditions. We produce safe and effective therapies for patients who rely on them for their quality of life, and sometimes for life itself. Innovation is at the heart of everything we do. It is reflected in our creation of state of the art plasma collection and manufacturing facilities, our investment in improving current therapies, finding new indications for existing therapies, and innovating new therapeutic products for unmet needs


Contact Information



Current Management

  • Paul Perreault / CEO, Managing Director
  • Paul Perreault / President, CEO
  • Mark Dehring / Director, Inv. Rel.
  • John Shine / Chairman

Current Share Structure

  • Market Cap: $3,080,522,556 - 03/09/2018
  • Authorized: 500,000,000 - 09/01/2015
  • Issue and Outstanding: 23,725,528 - 09/01/2015


Daily Technical Chart for (OTC: CSLLY)

Daily Technical Chart for (OTC: CSLLY)

Stay tuned for daily updates and more on (OTC: CSLLY)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: CSLLY)

Do your DD and if you choose, be ready to go!


The Research: All source information contained in this email is from the public sources mentioned below.



Thank you

DD Report



Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in CSLLY is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of CSLLY and does not buy, sell, or trade any shares of CSLLY. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: